Does New OS Data Move the Needle for Tivozanib in RCC?


<![CDATA[]]>(MedPage Today) — MIAMI — Will updated survival results from a randomized phase III trial open the doors for the embattled drug tivozanib as a later-line renal cell carcinoma (RCC)… Source link